Danaher

Danaher

Danaher Corporation (DHR) is a diversified science and technology company focused on life sciences, diagnostics and environmental & applied solutions. It supplies instruments, consumables, software and services used by research laboratories, hospitals and industrial customers worldwide. With a market capitalisation of about $155.94 billion, Danaher combines organic R&D-driven growth with disciplined acquisitions and operational rigor (the Danaher Business System) to drive recurring revenue and margin expansion. Investors often watch its exposure to healthcare spending, diagnostic cycles and capital-equipment demand. Strengths include a broad product portfolio, strong cash generation and a track record of integrating acquisitions; risks include execution on M&A, regulatory changes, cyclicality in capital spending and currency swings. Valuation can be premium given its defensive characteristics, but future returns are uncertain. This is general educational information, not personal investment advice — consider your goals and consult an authorised adviser before making investment decisions.

Why It's Moving

Danaher

Danaher's Bold Moves Fuel Analyst Bets on 27% Surge by 2026

With no major headlines in the past week, Danaher rides a wave of optimism from its life sciences tools sector, where analysts see robust upside amid undervaluation. Strategic expansions like the recent Masimo deal and dividend boost signal deepening strength in diagnostics and recurring revenue streams.
Sentiment:
🐃Bullish
  • Masimo's $9.9B acquisition expands Danaher's medtech footprint, blending patient monitoring tech to capture growing demand in connected healthcare.
  • 25% dividend hike underscores rock-solid cash flow and profitability, drawing income investors amid sector recovery.
  • Recurring consumables and life sciences demand normalization position Danaher for operating leverage, powering models toward 27%+ gains.

When is the next earnings date for Danaher (DHR)?

Danaher (NYSE: DHR) reported its Q1 2026 earnings on April 21, 2026. With that release now complete, the next earnings date is expected on or around July 22, 2026, covering the second quarter ending June 2026, consistent with the company's historical quarterly pattern. Investors should monitor official channels for any updates to the schedule.

Stock Performance Snapshot

Buy

Analyst Rating

Analysts recommend buying Danaher Corp. stock with a target price of $259.6, indicating potential growth.

Above Average

Financial Health

Danaher Corp. is performing well, with strong revenue, cash flow, and profit margins.

Below Average

Dividend

Danaher Corp.'s low dividend yield of 0.68% means it may not be ideal for dividend-seeking investors. If you invested $1000, you would be paid $6.80 a year in dividends (based on the last 12 months).

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Discover More Opportunities

ABT

Abbott

Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.

A

AGILENT TECHNOLOGIES INC

Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.

ALGN

ALIGN TECHNOLOGY INC

Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.

Baskets Featuring DHR

Healthcare Titans: Brazil Growth vs Currency Volatility

Healthcare Titans: Brazil Growth vs Currency Volatility

Brazil's healthcare sector is rapidly modernizing, creating significant demand for global innovation in areas like AI and digital health. This basket offers exposure to the US and EU-listed pharmaceutical, medical device, and technology titans that supply this growing market.

Published: October 14, 2025

Explore Basket
Activist Sparks Life Science Shakeup

Activist Sparks Life Science Shakeup

Activist investor Engine Capital is pushing for a sale of life-sciences company Avantor after taking a significant stake. This move could spark a wave of M&A across the life-sciences supply industry, creating opportunities for competitor firms and other potential acquisition targets.

Published: August 11, 2025

Explore Basket
Acquirer's Engine

Acquirer's Engine

Invest in companies with proven expertise in growth-by-acquisition. These carefully selected stocks represent businesses with exceptional management teams that consistently buy their way to market leadership and enhanced profitability through strategic M&A.

Published: June 17, 2025

Explore Basket

Why You’ll Want to Watch This Stock

📈

Recurring Revenue Engine

Consumables and service contracts support predictable recurring revenue and cash flow, though demand can vary with spending cycles.

🌍

Global Healthcare Reach

A broad international footprint offers diversification across markets, while currency moves and regional regulation remain potential headwinds.

Innovation & M&A

R&D and targeted acquisitions expand capabilities and addressable markets, but integration and valuation risks deserve attention.

Why invest with Nemo?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Frequently asked questions